This Microcap Just Dethroned a 20-Year Monopoly (And Nobody's Noticed)
From Zero to 10% Market Share in 4 Months: The $170M Pharma Nobody's Watching
To read our full disclaimer, click here.
There's a skin condition that affects 16 million Americans.
Makes their face red, inflamed, sometimes painful.
The psychological impact is brutal - people stop going out, avoid photos, skip social events.
For twenty years, one drug owned this market.
Doctors prescribed it because nothing else worked better. Patients paid up because they had no choice.
The market? $1.2 billion annually. The competition? Non-existent.
Until four months ago.
A microcap pharma company nobody's watching just launched a drug that beat the incumbent in head-to-head trials.
Better results, fewer side effects, same price point.
In April they had zero prescriptions.
By July they captured 10% market share.
The incumbent still controls 90% of the market. But the writing’s on the wall in my opinion.
Here's what makes this setup lethal:
Commercial launch: April 2025
Prescriptions written by July: 12,800
Month-over-month growth: 30-40%
Revenue per prescription: $380
Insurance coverage: 65% of commercial lives (up from 29% in May)
Patent protection: Until 2039
They're already at a $40M annual run rate. Management thinks they'll hit $200-300M at maturity.
The market values the entire company at $171M.
What they're missing: This isn't some speculative biotech burning cash on trials. They've got $56M in existing revenues, 50 sales reps already calling on dermatologists, and management that previously sold a company in this space for $2.5 billion.
The company is…